Trexquant Investment LP Sells 16,120 Shares of Penumbra, Inc. (NYSE:PEN)

Trexquant Investment LP cut its holdings in Penumbra, Inc. (NYSE:PEN - Free Report) by 64.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,854 shares of the company's stock after selling 16,120 shares during the period. Trexquant Investment LP's holdings in Penumbra were worth $2,103,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. UMB Bank n.a. grew its position in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $46,000 after purchasing an additional 70 shares in the last quarter. Mather Group LLC. boosted its stake in shares of Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after buying an additional 208 shares during the period. Jones Financial Companies Lllp grew its position in Penumbra by 25.0% during the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after buying an additional 75 shares in the last quarter. GAMMA Investing LLC increased its stake in Penumbra by 160.8% during the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company's stock worth $106,000 after acquiring an additional 275 shares during the period. Finally, Blue Trust Inc. raised its holdings in Penumbra by 43.4% in the 4th quarter. Blue Trust Inc. now owns 730 shares of the company's stock valued at $173,000 after acquiring an additional 221 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Trading Down 0.9 %

Shares of NYSE:PEN traded down $2.45 during mid-day trading on Monday, reaching $269.87. 38,367 shares of the company's stock were exchanged, compared to its average volume of 410,810. The firm has a market capitalization of $10.44 billion, a price-to-earnings ratio of 793.75, a PEG ratio of 2.83 and a beta of 0.56. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The business's fifty day moving average price is $274.33 and its 200-day moving average price is $249.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. On average, research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Activity

In other news, Director Thomas Wilder sold 360 shares of the company's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the transaction, the director now owns 4,533 shares in the company, valued at approximately $1,199,341.14. This represents a 7.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lambert Shiu sold 501 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $282.88, for a total value of $141,722.88. Following the completion of the sale, the chief accounting officer now owns 32,969 shares of the company's stock, valued at approximately $9,326,270.72. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 111,236 shares of company stock valued at $31,222,390 in the last ninety days. 5.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Bank of America assumed coverage on Penumbra in a research report on Friday, March 14th. They issued a "buy" rating and a $320.00 price target on the stock. Oppenheimer initiated coverage on shares of Penumbra in a research report on Tuesday, December 17th. They issued an "outperform" rating and a $275.00 target price for the company. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research report on Wednesday, February 19th. Piper Sandler restated an "overweight" rating and set a $330.00 price objective (up from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Finally, Robert W. Baird lifted their price target on Penumbra from $305.00 to $328.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $293.80.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.